Kinetic analysis of the toxicity of pharmaceutical excipients cremophor EL and RH40 on endothelial and epithelial cells

Journal of Pharmaceutical Sciences

Volumn 102, Issue 4, 2013, Pages 1173-1181

  Kiss, Lóránd ^a,b   Walter, Fruzsina R ^a   Bocsik, Alexandra ^a,b   Veszelka, Szilvia ^a   Ózsvári, Béla ^c   Puskás, László G ^c   Szabó révész, Piroska ^b   Deli, Mária A ^a  

^a INSTITUTE OF BIOCHEMISTRY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c AVIDIN LTD   (Hungary)

Author keywords

Absorption enhancer; Caco 2 cells; Cell toxicity; Cremophor; Endothelial; Epithelial; Excipient; Real time cell microelectric sensing; Surfactant; Toxicokinetics

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CLAUDIN 4; CLAUDIN 5; CREMOPHOR; LACTATE DEHYDROGENASE;

ARTICLE; CELL DAMAGE; CELL DEATH; CELL NUCLEUS; CYTOTOXICITY; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROCEDURES CONCERNING CELLS; REAL TIME CELL MICROELECTRONIC SENSING; TOXICOKINETICS;

EID: 84874698609     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23458     Document Type: Article

References (33)

1. Deli MA. 2009. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 1788:892-910.
2. Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharm Res 21:201-230.
3. Grant RL, Yao C, Gabaldon D, Acosta D. 1992. Evaluation of surfactant cytotoxicity potential by primary cultures of ocular tissues: I. Characterization of rabbit corneal epithelial cells and initial injury and delayed toxicity studies. Toxicology 76:153-176.
4. Gelderblom H, Verweij J, Nooter K, Sparreboom A. 2001. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598.
5. Weiszhár Z, Czúcz J, Révész C, Rosivall L, Szebeni J, Rozsnyay Z. 2012. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci 45:492-498.
6. Windebank AJ, Blexrud MD, de Groen PC. 1994. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 268:1051-1056.
7. Tatou E, Mossiat C, Maupoil V, Gabrielle F, David M, Rochette L. 1996. Effects of cyclosporin and cremophor on working rat heart and incidence of myocardial lipid peroxidation. Pharmacology 52:1-7.
8. Yamaguchi JY, Nishimura Y, Kanada A, Kobayashi M, Mishima K, Tatsuishi T, Iwase K, Oyama Y. 2005. Cremophor EL, a non-ionic surfactant, promotes Ca(2+)-dependent process of cell death in rat thymocytes. Toxicology 211:179-186.
9. Csóka K, Dhar S, Fridborg H, Larsson R, Nygren P. 1997. Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro. Cancer 79:1225-1233.
10. Maroju RK, Turner DC, Zhang H. 2010. Solubilizing efficiency and in vitro cytotoxicity of peptoad G. J Pharm Sci 99:2196-2198.
11. Sanchez H, Bigard X, Veksler V, Mettauer B, Lampert E, Lonsdorfer J, Ventura-Clapier R. 2000. Immunosuppressive treatment affects cardiac and skeletal muscle mitochondria by the toxic effect of vehicle. J Mol Cell Cardiol 32:323-331.
12. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. 2002. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 91:1991-2002.
13. Gutiérrez MB, Miguel BS, Villares C, Gallego JG, Tuñón MJ. 2006. Oxidative stress induced by Cremophor EL is not accompanied by changes in NF-kappaB activation or iNOS expression. Toxicology 222:125-131.
14. Cao FH, OuYang WQ, Wang YP, Yue PF, Li SP. 2011. A combination of a microemulsion and a phospholipid complex for topical delivery of oxymatrine. Arch Pharm Res 34:551-562.
15. Gursoy RN, Benita S. 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58:173-182.
16. Sakeer K, Al-Zein H, Hassan I, Desai S, Nokhodchi A. 2010. Enhancement of dissolution of nystatin from buccoadhesive tablets containing various surfactants and a solid dispersion formulation. Arch Pharm Res 33:1771-1779.
17. Horvát S, Fehér A, Wolburg H, Sipos P, Veszelka S, Tóth A, Kis L, Kurunczi A, Balogh G, Kürti L, Eros I, Szabó-Révész P, Deli MA. 2009. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. Eur J Pharm Biopharm 72:252-259.
18. Karpf DM, Holm R, Garafalo C, Levy E, Jacobsen J, Müllertz A. 2006. Effect of different surfactants in biorelevant medium on the secretion of a lipophilic compound in lipoproteins using Caco-2 cell culture. J Pharm Sci 95:45-55.
19. Kristmundsdóttir T, Aradóttir HA, Ingólfsdóttir K, Ogmundsdóttir HM. 2002. Solubilization of the lichen metabolite (+)-usnic acid for testing in tissue culture. J Pharm Pharmacol 54:1447-1452.
20. Deli MA, Ábrahám CS, Kataoka Y, Niwa M. 2005. Permeability studies on in vitro blood-brain barrier models: Physiology, pathology, and pharmacology. Cell Mol Neurobiol 25:59-127.
21. Veszelka S, Kittel Á, Deli MA. 2011. Tools of modelling blood-brain barrier penetrability. In Solubility, delivery, and ADME problems of drug and drug-candidates; Tihanyi K, Vastag M, Eds. Washington: Bentham Science Publ. Ltd., pp 166-188.
22. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, Masungi C, Maubon N, Mols R, Müllertz A, Mönkkönen J, O'Driscoll C, Oppers-Tiemissen HM, Ragnarsson EG, Rooseboom M, Ungell AL. 2008. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 35:383-96.
23. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. 2005. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872-1874.
24. Veszelka S, Pásztói M, Farkas AE, Krizbai I, Ngo TK, Niwa M, Ábrahám CS, Deli MA. 2007. Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Neurochem Int 50:219-228.
25. Ózsvári B, Puskás LG, Nagy LI, Kanizsai I, Gyuris M, Madácsi R, Fehér LZ, Gerö D, Szabó C. 2010. A cell-microelectronic sensing technique for the screening of cytoprotective compounds. Int J Mol Med 25:525-530.
26. Atienza JM, Yu N, Kirstein SL, Xi B, Wang X, Xu X, Abassi YA. 2006. Dynamic and label-free cell-based assays using the real-time cell electronic sensing system. Assay Drug Dev Technol 4:597-607.
27. Kürti L, Veszelka S, Bocsik A, Dung NT, Ózsvári B, Puskás LG, Kittel Á, Szabó-Révész P, Deli MA. 2012. The effect of sucrose esters on a culture model of the nasal barrier. Toxicol In Vitro 26:445-454.
28. Food and Drug Administration. Food and Drug Administration database for inactive ingredients in approved drug products. Accessed on 04 Dec 2012, at: http://www.accessdata.fda.gov/scripts/cder/iig/.
29. Groot RD, Rabone KL. 2001. Mesoscopic simulation of cell membrane damage, morphology change and rupture by nonionic surfactants. Biophys J 81:725-736.
30. Simons K, Toomre D. 2000. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1:31-39.
31. Dias VC, Wallace JL, Parsons HG. 1992. Modulation of cellular phospholipid fatty acids and leukotriene B4 synthesis in the human intestinal cell (CaCo-2). Gut 33:622-627.
32. Héliès-Toussaint C, Gambert S, Roller P, Tricot S, Lacour B, Grynberg A. 2006. Lipid metabolism in human endothelial cells. Biochim Biophys Acta 1761:765-774.
33. Christiansen A, Backensfeld T, Weitschies W. 2010. Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Eur J Pharm Sci 41:376-382.